4D Molecular Therapeutics, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- 4D Molecular Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2023-09-30 was $1.04M, a 940.00% increase year-over-year.
- 4D Molecular Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2023-06-30 was $894.00K, a 547.83% increase year-over-year.
- 4D Molecular Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2023-03-31 was $1.14M, a 243.94% increase year-over-year.
- 4D Molecular Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2022-09-30 was $100.00K.
- 4D Molecular Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2020 was $857.00K, a 1042.67% increase from fiscal 2019.
- 4D Molecular Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2019 was $75.00K.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2023-09-30 | $1.04M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $894.00K 10-Q · filed 2024-11-13 | |
| 2023-03-31 | $1.14M 10-Q · filed 2024-11-13 | |
| 2022-09-30 | $100.00K 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $138.00K 10-Q · filed 2023-11-09 | |
| 2022-03-31 | $330.00K 10-Q · filed 2023-11-09 | |
| 2021-03-31 | $99.00K 10-Q · filed 2022-11-08 | |
| 2020-12-31 | $857.00K 10-K · filed 2022-03-28 | |
| 2020-09-30 | $552.00K 10-Q · filed 2021-11-10 | |
| 2020-03-31 | $5.00K 10-Q · filed 2021-11-10 | |
| 2019-12-31 | $75.00K 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |